CHROMagar™ B.cepacia

For detection and enumeration of *Burkholderia cepacia* complex



CHROMagar™
The Chromogenic Media Pioneer

Burkholderia cepacia: A Multifaceted Pat

Overview

The ***Burkholderia cepacia* complex** (BCC) includes a group of bacteria that can pose **serious health risks** for people with **cystic fibrosis** (CF). The concerns about BCC from its ability to **spread among patients**, due to its capacity to form **biofilms**, and through **non-sterile**, **water-based pharmaceutical products**.
Certain strains of this group are highly virulent, such as *B. cenocepacia* ET12[1], which are associated with «**cepacia syndrome**.» This condition often leads to deadly decline in lung function, **resulting in high mortality** rates up to **75 %**[2].

***Burkholderia* species** are often **resistant** to **many antibiotics** [3] :
- Aminoglycosides,
- Quinolones
- β-lactams

A threat to patients with Cystic Fibrosis (CF)

+50,000
cases across 31 European countries (**16%** increase in 6 years)[4]

60%
of patients with BCC infection developed a chronic infection[4]

CF is a genetic disorder that damages the lungs, digestive system, and other organs

Despite advancements in CFTR modulators that extend life, lung infections remain a major burden.

Over 80%[5] of CF patients die from respiratory failure due to chronic infections and airway inflammation.

Despite no consensus, microbiological monitoring every 3 to 6 months is recommended to manage risks[6]

A Common Contaminant in Pharmaceutical Industries

One of the most commonly reported contaminants of nonsterile pharmaceutical products[7]

Over the past decade, at least 50 pharmaceutical companies have faced products recalls due contamination, resulting in financial loss and reputational damage.[8]

The average outbreak duration was about 6 months[9]



Many articles highlight that **water-based pharmaceutical products** are linked to **numerous outbreaks**, especially impacting the **USA and India**, involving various **types of products**[10]

Products	Nb of outbreak
Medical Materials	5
Mouthwash	5
Ultrasound Gel	4
Saline Flushes	4
Antiseptic	3

thogen in CF Patients

CHROMagar™ **B.cepacia** is a **selective chromogenic culture medium** that is intended for use in the qualitative direct detection, **differentiation** and **presumptive identification** of ***Burkholderia cepacia* complex (BCC)** bacteria colonization in **cystic fibrosis patients**. Additionally, CHROMagar™ B.cepacia can be employed for the **qualitative** or **quantitative analysis of BCC** in **non-sterile, water-based pharmaceutical products**, in accordance with **USP <60> guidelines**.



Sensitivity[11] ≈ 100%
Specificity[11] = 95%

Medium performance

RESULTS:
Can be interpreted within 36/72h of aerobic incubation at 35-37 °C

LIMITS CONTAMINANTS:
Mold is largely inhibited.

HIGH INTENSITY:
Burkholderia cepacia complex (BCC) colonies develop with an intense green-blue colour, clearly visible to the naked eye.

DIVERSE AREAS OF APPLICATION:
It allows for the cultivation of clinical and pharmaceutical samples, facilitating the diagnosis of Bcc infections.

SAMPLES:
Broncho-alveolar lavages, sputum, nasopharyngeal aspirations, and oropharyngeal swabs, urine and stools samples. Non-sterile products and purified water.

ALL IN ONE:
Save time, the pre-weighed medium powder can be added to distilled water. No supplement is required.

[1] Somayaji et al. 2020. Ann Am Thorac Soc.
[2] Hedary et al. 2024. Cureus.
[3] Shmarina et al. 2024. Front Cell Infect Microbiol.
[4] https://www.ecfs.eu/
[5] Bhagirath et al. 2016. BMC Pulm Med.
[6] Practical Guidance for Clinical Microbiology Laboratories , Chinese Alliance for Rare Lung Diseases
[7] Tavares et al. 2020. Clin Microbiol Rev.
[8] Duonget al. 2024. PLoS One.
[9] Häfligeret al. 2020 Infect Prev Pract.
[10] Guo et al. 2017. Am J Infect Control. , Gleeson et al. 2019. Perit Dial Int., Greendyke et al. 2018. Open Forum Infect Dis., Find all articles in annex or get in touch with us.
[11] Masotti et al. 2021. RICAI

Clinical Microbiology : Empowering Detection

CHROMagar™ has developed a range of selective culture media for the rapid detection of clinically relevant pathogens, enhancing diagnostic speed and accuracy for better patient outcomes.


CHROMagar™ Acinetobacter


CHROMagar™ Orientation


CHROMagar™ STEC


CHROMagar™ Candida Plus


CHROMagar™ Salmonella


CHROMagar™ Strep A


CHROMagar™ C.difficile


CHROMagar™ Serratia


CHROMagar™ Strep B


CHROMagar™ Campylobacter


CHROMagar™ Staph aureus


LIM RambaQUICK™ Strep B

ASK YOUR **LOCAL DISTRIBUTOR** FOR **MORE INFORMATION**

Reference contact :

CHROMagar™
The Chromogenic Media Pioneer

CHROMagar.com
CHROMagar, 29 avenue George Sand, 93210 La Plaine Saint-Denis, France
For more informations about our products and technical documents, please refer to our website.

LF-EXT-097-EN